Evaluation of Severe Myalgia Induced by Continuous ‐Infusion Bumetanide in Patients with Acute Heart Failure

ConclusionThe incidence of severe myalgia in patients with AHF receiving bumetanide infusion was 5.8%, 29 ‐fold higher than incidence rate listed in the package labeling. Patients receiving infusion rates>1 mg/hour were 4 ‐fold more likely to experience bumetanide‐induced severe myalgia than those receiving rates ≤1 mg/hour.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: Brief Report Source Type: research